相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation
Carolyn A. Luscombe et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations
Emmanuel Ndashimye et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Clinical targeting of HIV capsid protein with a long-acting small molecule
John O. Link et al.
NATURE (2020)
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda
Emmanuel Ndashimye et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
Joseph Fokam et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2020)
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor
Stephanie M. Bester et al.
SCIENCE (2020)
Dolutegravir Resistance and Failure in a Kenyan Patient
Loice Achieng et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug- Resistant HIV-1 Infection
Mario V. Beccari et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
HIV subtype diversity worldwide
Nicholas Bbosa et al.
CURRENT OPINION IN HIV AND AIDS (2019)
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing
Audrey Vautrin et al.
SCIENTIFIC REPORTS (2019)
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Alison J. Rodger et al.
LANCET (2019)
GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds
Kamal Singh et al.
FRONTIERS IN MICROBIOLOGY (2019)
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model
Stephen R. Yant et al.
NATURE MEDICINE (2019)
The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030
Emmanuel Ndashimye et al.
INFECTIOUS DISEASES OF POVERTY (2019)
Phylogenetic measures of indel rate variation among the HIV-1 group M subtypes
John Palmer et al.
VIRUS EVOLUTION (2019)
Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana
Kaelo K. Seatla et al.
AIDS (2018)
Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda
Emmanuel Ndashimye et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2018)
Molecular epidemiology of HIV-1 subtype A in former Soviet Union countries
Lazzat Aibekova et al.
PLOS ONE (2018)
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Steven J. Smith et al.
RETROVIROLOGY (2018)
Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
Abu Bakar Siddik et al.
SCIENTIFIC REPORTS (2018)
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients
Marine Perrier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
High Time to Start Human Immunodeficiency Virus Type 1-Infected Patients on Integrase Inhibitors in Sub-Saharan Africa
Emmanuel Ndashimye
JOURNAL OF INFECTIOUS DISEASES (2017)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
Marie Pancera et al.
NATURE CHEMICAL BIOLOGY (2017)
Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy
Simona A. Iacob et al.
FRONTIERS IN MICROBIOLOGY (2017)
MK-8591 (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture
Vincent H. Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
Jean-Marc Steens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Genetic characterization of human immunodeficiency virus type 1 transmission in the Middle East and North Africa
Malik Sallam et al.
HELIYON (2017)
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors
Emiko Urano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals
Teresa Llacer Delicado et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection
John Wilkinson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs
Denis M. Tebit et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)
C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors
Zheng Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
HIV-1 drug resistance and resistance testing
Dana S. Clutter et al.
INFECTION GENETICS AND EVOLUTION (2016)
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
Alison J. Rodger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
An atomic model of HIV-1 capsid-SP1 reveals structures regulating assembly and maturation
Florian K. M. Schur et al.
SCIENCE (2016)
Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis
Manjula Gunawardana et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
HIV-1 Group O Resistance Against Integrase Inhibitors
Agnes Depatureaux et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
Tomas Doyle et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis
Noelie Campos et al.
RETROVIROLOGY (2015)
An integrated map of HIV genome-wide variation from a population perspective
Guangdi Li et al.
RETROVIROLOGY (2015)
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes
Djeneba B. Fofana et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
David R. Langley et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2015)
E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings
Nicolas Sluis-Cremer et al.
ANTIVIRAL RESEARCH (2014)
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068
Nannan Zhou et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors
Zhufang Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope
Craig S. Pace et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5-and X4-tropic HIV-1 subtype B
Cathia Soulie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
New Betulinic Acid Derivatives for Bevirimat-Resistant Human Immunodeficiency Virus Type-1
Zhao Dang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120
Annette N. Ratcliff et al.
JOURNAL OF VIROLOGY (2013)
Functional conservation of HIV-1 Gag: implications for rational drug design
Guangdi Li et al.
RETROVIROLOGY (2013)
Effect of Natural Polymorphisms in the HIV-1 CRF02_AG Protease on Protease Inhibitor Hypersusceptibility
Andre F. A. Santos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Frequent Emergence of N348I in HIV-1 Subtype C Reverse Transcriptase with Failure of Initial Therapy Reduces Susceptibility to Reverse-Transcriptase Inhibitors
Jessica H. Brehm et al.
CLINICAL INFECTIOUS DISEASES (2012)
Genetic Barrier to the Development of Resistance to Integrase Inhibitors in HIV-1 Subtypes CRF01_AE and B
Hai Le Nguyen et al.
INTERVIROLOGY (2012)
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients
Charlotte Charpentier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors
Jorge L. Martinez-Cajas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Presence of CXCR4-Using HIV-1 in Patients With Recently Diagnosed Infection: Correlates and Evidence for Transmission
Kristen Chalmet et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
Peter K. Quashie et al.
JOURNAL OF VIROLOGY (2012)
Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein
Christopher T. Lemke et al.
JOURNAL OF VIROLOGY (2012)
The structural biology of HIV-1: mechanistic and therapeutic insights
Alan Engelman et al.
NATURE REVIEWS MICROBIOLOGY (2012)
Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line Therapy
B. Chaplin et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2011)
A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat
Wuxun Lu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience
Carolina Garrido et al.
ANTIVIRAL RESEARCH (2011)
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
Isabelle Malet et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Subtype Diversity Associated with the Development of HIV-1 Resistance to Integrase Inhibitors
Bluma G. Brenner et al.
JOURNAL OF MEDICAL VIROLOGY (2011)
Investigating the Role of Metal Chelation in HIV-1 Integrase Strand Transfer Inhibitors
Alessia Bacchi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab
Jonathan Toma et al.
JOURNAL OF VIROLOGY (2011)
HIV-1 IN Strand Transfer Chelating Inhibitors: A Focus on Metal Binding
Alessia Bacchi et al.
MOLECULAR PHARMACEUTICS (2011)
The HIV-1 Vpu Viroporin Inhibitor BIT225 Does Not Affect Vpu-Mediated Tetherin Antagonism
Bjoern D. Kuhl et al.
PLOS ONE (2011)
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles
Albert T. Nguyen et al.
RETROVIROLOGY (2011)
Origins of HIV and the AIDS Pandemic
Paul M. Sharp et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2011)
High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor
Eduardo Seclen et al.
AIDS (2010)
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
Tamara Bar-Magen et al.
AIDS (2010)
Antiviral Efficacy of the Novel Compound BIT225 against HIV-1 Release from Human Macrophages
Gabriela Khoury et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes
Irene Lisovsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-α-2b and nucleoside analogues
Carolyn A. Luscombe et al.
ANTIVIRAL RESEARCH (2010)
Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection
Carolina Garrido et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Low Frequency of CXCR4-Using Viruses in Patients at the Time of Primary Non-Subtype-B HIV-1 Infection
Pierre Frange et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase
Viktor von Wyl et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Retroviral intasome assembly and inhibition of DNA strand transfer
Stephen Hare et al.
NATURE (2010)
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Stephen Hare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
HIV-1 Entry, Inhibitors, and Resistance
Michael A. Lobritz et al.
VIRUSES-BASEL (2010)
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy
Philippa J. Easterbrook et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2010)
HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention
Wade S. Blair et al.
PLOS PATHOGENS (2010)
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing
John Archer et al.
AIDS (2009)
Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
Kathryn M. Kitrinos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1
Kurt Van Baelen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Implications of HIV-1 M Group Polymorphisms on Integrase Inhibitor Efficacy and Resistance: Genetic and Structural in Silico Analyses
Eriketi Z. Loizidou et al.
BIOCHEMISTRY (2009)
Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa
Christopher J. Hoffmann et al.
CLINICAL INFECTIOUS DISEASES (2009)
Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy
Anna Maria Geretti et al.
CLINICAL INFECTIOUS DISEASES (2009)
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure
Ana T. Dumans et al.
INFECTION GENETICS AND EVOLUTION (2009)
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis
Ravindra K. Gupta et al.
LANCET INFECTIOUS DISEASES (2009)
HIV-1 tropism and survival in vertically infected Ugandan infants
Jessica D. Church et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase
Richard E. Myers et al.
JOURNAL OF VIROLOGY (2008)
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
Atsuko Hachiya et al.
JOURNAL OF VIROLOGY (2008)
Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors
Soo-Yon Rhee et al.
RETROVIROLOGY (2008)
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
Soo-Huey Yap et al.
PLOS MEDICINE (2007)
HIV drug development: the next 25 years
Charles Flexner
NATURE REVIEWS DRUG DISCOVERY (2007)
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations
Wei Huang et al.
JOURNAL OF VIROLOGY (2007)
Clade-specific differences between human immunodeficiency virus type 1 clades B and C: Diversity and correlations in C3-V4 regions of gp120
S. Gnanakaran et al.
JOURNAL OF VIROLOGY (2007)
Resistance and viral subtypes: how important are the differences and why do they occur?
Bluma G. Brenner
CURRENT OPINION IN HIV AND AIDS (2007)
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV
Anneleen Hombrouck et al.
PLOS PATHOGENS (2007)
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance
Galina N. Nikolenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C
Esmeralda A. J. M. Soares et al.
PLOS ONE (2007)
Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope
Art F. Y. Poon et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)
Catherine S. Adamson et al.
JOURNAL OF VIROLOGY (2006)
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004
Joris Hemelaar et al.
AIDS (2006)
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1
Jose D. Murga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
Bluma G. Brenner et al.
AIDS (2006)
3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro
M Sakalian et al.
JOURNAL OF VIROLOGY (2006)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2
T. Melby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
HIV-1 subtype C in vitro growth and coreceptor utilization
T Ndung'u et al.
VIROLOGY (2006)
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
J Snoeck et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
HIV-1 subtypes: epidemiology and significance fov HIV management
AM Geretti
CURRENT OPINION IN INFECTIOUS DISEASES (2006)
K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients
RK Gupta et al.
AIDS (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
A peptide inhibitor of HIV-1 assembly in vitro
J Sticht et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme
MC Bellocchi et al.
JOURNAL OF MEDICAL VIROLOGY (2005)
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP
SH Eshleman et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
The HIV coreceptor switch: a population dynamical perspective
RR Regoes et al.
TRENDS IN MICROBIOLOGY (2005)
Low accumulation of L90M in protease from subtype FHIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism
A Calazans et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients
R Carmona et al.
JOURNAL OF CLINICAL VIROLOGY (2005)
Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors
Y Gao et al.
JOURNAL OF VIROLOGY (2004)
Genetic variation at NNRT1 resistance-associated positions in patients infected with HIV-1 subtype C
Z Grossman et al.
AIDS (2004)
Differences in frequencies of drug resistance-associated mutations in the HIV-1 pol gene of B subtype and BF intersubtype recombinant samples
MG Carobene et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases
LMF Gonzalez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups
E Tuaillon et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes
A Holguín et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Epidemiologic and Molecular Characterization of Human Immunodeficiency Virus Type 1 in Southern Brazil
Esmeralda A. J. M. Soares et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir
LMF Gonzalez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Antiviral inhibition of the HIV-1 capsid protein
C Tang et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
B Brenner et al.
AIDS (2003)
Genetic divergence of human immunodeficiency virus type I Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT
H Loemba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
AIDS - Diversity considerations in HIV-1 vaccine selection
B Gaschen et al.
SCIENCE (2002)
Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes
JA Grobler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2001)
Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B
Z Grossman et al.
AIDS (2001)
Evolutionary and immunological implications of contemporary HIV-1 variation
B Korber et al.
BRITISH MEDICAL BULLETIN (2001)
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide
D Pieniazek et al.
AIDS (2000)
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
RM Gulick et al.
ANNALS OF INTERNAL MEDICINE (2000)
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs
VS Torre et al.
JOURNAL OF VIROLOGY (2000)
分享论文
